Profile data is unavailable for this security.
About the company
Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company’s lead engineered hematopoietic stem cells (eHSC) product candidate include tremtelectogene empogeditemcel (trem-cel), for the treatment for acute myeloid leukemia (AML) and other blood cancers. It is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of trem-cel in patients with AML.
- Revenue in USD (TTM)0.00
- Net income in USD-117.86m
- Incorporated2015
- Employees168.00
- LocationVor Biopharma Inc100 Cambridgepark Drive, Suite 101CAMBRIDGE 02140United StatesUSA
- Phone+1 (617) 655-6580
- Fax+1 (302) 655-5049
- Websitehttps://www.vorbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Omega Therapeutics Inc | 4.94m | -92.28m | 108.10m | 93.00 | -- | 2.61 | -- | 21.89 | -1.67 | -1.67 | 0.0896 | 0.7498 | 0.029 | -- | 6.08 | 53,107.53 | -54.28 | -- | -62.10 | -- | -- | -- | -1,868.35 | -- | -- | -- | 0.302 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
| Armata Pharmaceuticals Inc | 4.70m | -79.58m | 111.76m | 66.00 | -- | -- | -- | 23.78 | -2.20 | -2.20 | 0.1302 | -1.56 | 0.041 | -- | 3.16 | 71,196.97 | -69.46 | -59.78 | -235.17 | -72.70 | -- | -- | -1,693.47 | -1,113.72 | -- | -1.11 | 1.75 | -- | -17.77 | -- | -87.03 | -- | 184.10 | -- |
| Immunic Inc | 0.00 | -97.92m | 114.40m | 77.00 | -- | 1.37 | -- | -- | -1.84 | -1.84 | 0.00 | 0.9278 | 0.00 | -- | -- | 0.00 | -91.94 | -72.09 | -110.91 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
| FibroGen Inc | 167.49m | -240.46m | 115.39m | 486.00 | -- | -- | -- | 0.6889 | -2.45 | -2.45 | 1.70 | -2.29 | 0.3704 | 1.18 | 5.05 | 344,635.80 | -53.71 | -30.62 | -124.24 | -42.31 | 75.46 | 93.52 | -145.02 | -119.08 | 1.27 | -36.51 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
| Sangamo Therapeutics Inc | 18.76m | -328.05m | 116.49m | 405.00 | -- | 2.02 | -- | 6.21 | -1.86 | -1.86 | 0.1057 | 0.2784 | 0.0659 | -- | 4.86 | 46,311.11 | -115.20 | -26.09 | -139.17 | -31.04 | -- | -- | -1,749.06 | -136.53 | -- | -- | 0.00 | -- | 58.34 | 15.85 | -34.09 | -- | -13.25 | -- |
| aTyr Pharma Inc | 588.00k | -53.93m | 116.63m | 56.00 | -- | 1.37 | -- | 198.35 | -0.9029 | -0.9029 | 0.0099 | 1.24 | 0.0047 | -- | 0.2868 | 10,500.00 | -43.13 | -45.45 | -48.85 | -52.74 | -- | -- | -9,172.11 | -784.19 | -- | -- | 0.021 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
| Vor Biopharma Inc | 0.00 | -117.86m | 116.65m | 168.00 | -- | 0.7702 | -- | -- | -1.75 | -1.75 | 0.00 | 2.22 | 0.00 | -- | -- | 0.00 | -47.38 | -45.79 | -50.28 | -48.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.98 | -- | -- | -- |
| Nuvectis Pharma Inc | 0.00 | -22.26m | 117.57m | 13.00 | -- | 9.14 | -- | -- | -1.42 | -1.42 | 0.00 | 0.7005 | 0.00 | -- | -- | 0.00 | -112.45 | -- | -168.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.64 | -- | -- | -- |
| Vistagen Therapeutics Inc | 1.04m | -32.07m | 118.10m | 37.00 | -- | 0.958 | -- | 113.31 | -3.56 | -3.56 | 0.0775 | 4.56 | 0.013 | -- | -- | 31,584.85 | -39.89 | -77.80 | -42.10 | -85.00 | -- | -- | -3,076.62 | -8,640.25 | -- | -- | 0.00006 | -- | -120.50 | -- | -21.64 | -- | 165.73 | -- |
| DiaMedica Therapeutics Inc | 0.00 | -19.38m | 118.45m | 18.00 | -- | 2.32 | -- | -- | -0.6168 | -0.6168 | 0.00 | 1.35 | 0.00 | -- | -- | 0.00 | -43.77 | -45.38 | -46.37 | -48.24 | -- | -- | -- | -- | -- | -- | 0.00008 | -- | -- | -- | -41.72 | -- | -13.65 | -- |
| Amylyx Pharmaceuticals Inc | 398.00m | -71.10m | 119.35m | 384.00 | -- | 0.3677 | -- | 0.2999 | -1.07 | -1.07 | 5.74 | 4.77 | 0.9644 | 6.74 | 21.00 | 1,036,461.00 | -17.23 | -- | -20.84 | -- | 88.93 | -- | -17.86 | -- | 4.48 | -- | 0.00 | -- | 1,612.94 | -- | 124.84 | -- | -- | -- |
| Vigil Neuroscience Inc | 0.00 | -82.78m | 119.52m | 65.00 | -- | 1.15 | -- | -- | -2.12 | -2.12 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -52.16 | -- | -54.92 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
| Coya Therapeutics Inc | 6.00m | -7.99m | 119.88m | 8.00 | -- | 3.32 | -- | 19.97 | -0.8219 | -0.8219 | 0.5906 | 2.47 | 0.2417 | -- | -- | 750,276.30 | -32.17 | -- | -39.17 | -- | -- | -- | -133.08 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
| Rezolute Inc | 0.00 | -56.83m | 119.98m | 51.00 | -- | 1.29 | -- | -- | -1.11 | -1.11 | 0.00 | 2.31 | 0.00 | -- | -- | 0.00 | -45.04 | -58.48 | -47.75 | -63.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.13 | -- | 92.29 | -- |
| Adicet Bio Inc | 0.00 | -142.66m | 120.79m | 143.00 | -- | 0.3738 | -- | -- | -3.32 | -3.32 | 0.00 | 3.93 | 0.00 | -- | -- | 0.00 | -53.03 | -37.03 | -57.18 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| Vaxart Inc | 7.38m | -82.47m | 124.67m | 109.00 | -- | 1.87 | -- | 16.90 | -0.5844 | -0.5844 | 0.0519 | 0.3767 | 0.0601 | -- | 4.87 | 67,697.25 | -67.13 | -49.60 | -77.06 | -54.86 | -- | -- | -1,117.56 | -1,398.00 | -- | -- | 0.10 | -- | 6,796.26 | 12.15 | 23.47 | -- | 21.49 | -- |
Data as of May 10 2024. Currency figures normalised to Vor Biopharma Inc's reporting currency: US Dollar USD
71.22%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 31 Dec 2023 | 22.75m | 33.37% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 7.52m | 11.03% |
| Paradigm BioCapital Advisors LPas of 31 Dec 2023 | 6.46m | 9.47% |
| Laurion Capital Management LPas of 31 Dec 2023 | 3.18m | 4.67% |
| Invus Public Equities Advisors LLCas of 31 Dec 2023 | 2.35m | 3.44% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 2.05m | 3.01% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.72m | 2.52% |
| Woodline Partners LPas of 31 Dec 2023 | 1.11m | 1.63% |
| Geode Capital Management LLCas of 31 Dec 2023 | 794.06k | 1.17% |
| Sarissa Capital Management LPas of 31 Dec 2023 | 618.00k | 0.91% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
